IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-19568-1.html
   My bibliography  Save this article

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Author

Listed:
  • Shuang Wang

    (Mabwell (Shanghai) Bioscience Co., Ltd
    Beijing Kohnoor Science & Technology Co., Ltd)

  • Yun Peng

    (Chinese Academy of Sciences)

  • Rongjuan Wang

    (Mabwell (Shanghai) Bioscience Co., Ltd
    Beijing Kohnoor Science & Technology Co., Ltd)

  • Shasha Jiao

    (Mabwell (Shanghai) Bioscience Co., Ltd
    Beijing Kohnoor Science & Technology Co., Ltd)

  • Min Wang

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Weijin Huang

    (National Institutes for Food and Drug Control)

  • Chao Shan

    (Chinese Academy of Sciences)

  • Wen Jiang

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Zepeng Li

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Chunying Gu

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Ben Chen

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Xue Hu

    (Chinese Academy of Sciences)

  • Yanfeng Yao

    (Chinese Academy of Sciences)

  • Juan Min

    (Chinese Academy of Sciences)

  • Huajun Zhang

    (Chinese Academy of Sciences)

  • Ying Chen

    (Chinese Academy of Sciences)

  • Ge Gao

    (Chinese Academy of Sciences)

  • Peipei Tang

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Gang Li

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • An Wang

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Lan Wang

    (National Institutes for Food and Drug Control)

  • Jinchao Zhang

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Shuo Chen

    (University of Oxford)

  • Xun Gui

    (Mabwell (Shanghai) Bioscience Co., Ltd)

  • Zhiming Yuan

    (Chinese Academy of Sciences)

  • Datao Liu

    (Mabwell (Shanghai) Bioscience Co., Ltd)

Abstract

Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.

Suggested Citation

  • Shuang Wang & Yun Peng & Rongjuan Wang & Shasha Jiao & Min Wang & Weijin Huang & Chao Shan & Wen Jiang & Zepeng Li & Chunying Gu & Ben Chen & Xue Hu & Yanfeng Yao & Juan Min & Huajun Zhang & Ying Chen, 2020. "Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys," Nature Communications, Nature, vol. 11(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19568-1
    DOI: 10.1038/s41467-020-19568-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-19568-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-19568-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Pauline Maisonnasse & Yoann Aldon & Aurélien Marc & Romain Marlin & Nathalie Dereuddre-Bosquet & Natalia A. Kuzmina & Alec W. Freyn & Jonne L. Snitselaar & Antonio Gonçalves & Tom G. Caniels & Judith , 2021. "COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models," Nature Communications, Nature, vol. 12(1), pages 1-10, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19568-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.